Baird analyst Brian Skorney lowered the firm’s price target on Crinetics to $43 from $48 and keeps an Outperform rating on the shares. The firm said its 2Q23 financials largely met expectations, with the two Ph3 trials of paltusotine in acromegaly on track to read-out over the next 6 months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRNX: